Jazz Pharmaceuticals stock analysis
Jazz Pharmaceuticals (J7Z) Stock Price & Analysis
J7Z Stock Chart & Stats
- Day’s Range
- N/A
- 52-Week Range
- N/A
- Previous Close
- N/A
- Volume
- N/A
- Average Volume (3M)
- N/A
- Market Cap
- CHF 12.76B
- Enterprise Value
- CHF 17.77B
- Total Cash (Recent Filing)
- CHF 2.86B
- Total Debt (Recent Filing)
- CHF 5.64B
- Price to Earnings (P/E)
- 64.3
- Beta
- 0.34
- Next Earnings
- Mar 02, 2027 (Est.)
- EPS Estimate
- 5.87
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Strong Cash Generation
Robust operating and free cash flow gives Jazz internal funding capacity for product launches, pipeline development, acquisitions and debt management. Because cash generation has generally tracked reported earnings, it also supports the quality and durability of the company’s operating model.
High-margin Growth Platform
Raised revenue guidance alongside very high gross-margin expectations indicates that Jazz is expanding while retaining substantial economics on product sales. This supports reinvestment in commercial execution and research, and provides operating leverage as newer therapies scale.
Product And Pipeline Expansion
Jazz is strengthening its long-term portfolio through an oncology launch with meaningful clinical differentiation and a rare-epilepsy pipeline addition. These assets broaden therapeutic exposure beyond existing products and create opportunities for future growth in specialized markets.
Bears Say
Elevated Leverage
Elevated debt reduces financial flexibility even though leverage has improved from 2022 levels. Interest obligations and refinancing needs can constrain investment choices, particularly if product growth slows or Jazz must fund additional acquisitions and development programs.
Earnings And Margin Volatility
Strong gross margins have not translated into consistently stable earnings, with profitability moving from solid results to a loss and then only a modest recovery. Royalty costs, technology transfers and rising investment spending may continue to pressure earnings conversion.
Zepzelca Competitive Pressure
Expected competition in first-line maintenance small-cell lung cancer creates a structural risk to Zepzelca’s future contribution. If the competing therapy gains approval and reimbursement, Jazz may face weaker demand, reduced market share or greater commercial spending.
Jazz Pharmaceuticals News
Jazz’s Epidyolex Follow-Up Study Reaches Completion: What It Means for JAZZ Investors
Jazz Pharmaceuticals ($JAZZ) announced an update on their ongoing clinical study. Study Overview: Jazz Pharmaceuticals’ NCT05772429 study, titled “Long-term Follow-up of a Multicentre, Non-interventional, Prospective Cohort of Participants Prescribed Epidyolex
J7Z FAQ
What is Jazz Pharmaceuticals’s market cap?
When is Jazz Pharmaceuticals’s upcoming earnings report date?
How were Jazz Pharmaceuticals’s earnings last quarter?
Is Jazz Pharmaceuticals overvalued?
Does Jazz Pharmaceuticals pay dividends?
What is Jazz Pharmaceuticals’s EPS estimate?
How many shares outstanding does Jazz Pharmaceuticals have?
What happened to Jazz Pharmaceuticals’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Jazz Pharmaceuticals?
What is the TipRanks Smart Score and how is it calculated?
Jazz Pharmaceuticals Stock Smart Score
Company Description
Jazz Pharmaceuticals
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Renee D. Gala
- Employees
- 2,890
- Website
- www.jazzpharma.com
- Address
- Waterloo Exchange, Dublin, DU, D04 E5W7, IE
Jazz Pharmaceuticals (J7Z) Earnings & Revenues
J7Z Company Deck
J7Z Earnings Call
Earnings Call SentimentPositive
The call was strongly positive. Jazz reported record revenue, raised full-year revenue and gross-margin guidance, delivered strong growth across oncology and Xywav, and described an encouraging early launch for Ziihera supported by favorable clinical data and market access. The company also highlighted substantial cash generation, pipeline progress and the Actio acquisition. Offsetting factors included lower adjusted gross margin, a reported non-GAAP loss driven by the Actio acquired IPR&D charge, a measured near-term Modeyso revenue pace, and future competitive pressure for Zepzelca. The positive operating and strategic developments significantly outweighed the stated challenges.
View all CH:J7Z earnings summaries











